Grifols, S.A. (NASDAQ:GRFS) Short Interest Update

Grifols, S.A. (NASDAQ:GRFS) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 2,710,000 shares, a decline of 28.9% from the February 28th total of 3,810,000 shares. Based on an average trading volume of 991,800 shares, the days-to-cover ratio is currently 2.7 days. Approximately 1.1% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Morgan Stanley assumed coverage on shares of Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating on the stock.

Grifols Price Performance

Shares of Grifols stock traded down $0.04 on Friday, reaching $7.27. The company’s stock had a trading volume of 586,558 shares, compared to its average volume of 1,231,491. Grifols has a 52-week low of $5.79 and a 52-week high of $9.96. The company has a market capitalization of $5.00 billion, a P/E ratio of 6.21 and a beta of 0.35. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The stock has a 50-day moving average price of $7.56 and a 200-day moving average price of $8.05.

Institutional Trading of Grifols

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its holdings in Grifols by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 31,543 shares of the biotechnology company’s stock worth $280,000 after buying an additional 2,301 shares during the last quarter. Hantz Financial Services Inc. lifted its position in shares of Grifols by 23.5% in the third quarter. Hantz Financial Services Inc. now owns 241,812 shares of the biotechnology company’s stock valued at $2,147,000 after acquiring an additional 45,997 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Grifols during the third quarter worth approximately $2,636,000. Erste Asset Management GmbH acquired a new position in Grifols in the 3rd quarter valued at $242,000. Finally, HighTower Advisors LLC lifted its holdings in Grifols by 12.5% in the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 1,546 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.